Skip directly to content

Research Toward a Cure Trials Supplemental References Page

Treatment Intensification/Early Treatment

AAHIV/RV254: Antiretroviral therapy for acute HIV infection
NCT00796263

Establish and characterize an acute HIV infection cohort in a high-risk population
NCT00796146 (related observational study)

References

Hellmuth J, Slike BM, Sacdalan C, et al. Very early ART initiation during acute HIV infection is associated with normalization of cerebrospinal fluid but not plasma markers of immune activation. J Infect Dis. 2019 Jan 21. doi: 10.1093/infdis/jiz030. [Epub ahead of print]

Chintanaphol M, Sacdalan C, Chottanapund S, et al. Brief Report: Safety and Tolerability of Inguinal Lymph Node Biopsy in Individuals With Acute HIV Infection in Thailand. J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):244-248. doi: 10.1097/QAI.0000000000001780.

Samboju V, Philippi CL, Chan P, et al. Structural and functional brain imaging in acute HIV. Neuroimage Clin. 2018 Jul 27;20:327-335. doi: 10.1016/j.nicl.2018.07.024. 

Kroon E, Pham PT, Sirivichayakul S, et al. Transmission dynamics among participants initiating antiretroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand. AIDS. 2018 Oct 23;32(16):2373-2381. doi: 10.1097/QAD.0000000000001956. 

Chintanaphol M, Sacdalan C, Chottanapund S, et al. Brief Report: Safety and Tolerability of Inguinal Lymph Node Biopsy in Individuals With Acute HIV Infection in Thailand. J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):244-248. doi: 10.1097/QAI.0000000000001780.

D'Antoni ML, Byron MM, Chan P, et al. Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. J Infect Dis. 2018 Sep 22;218(9):1453-1463. doi: 10.1093/infdis/jiy337.

Chan P, Patel P, Hellmuth J, et al. Distribution of Human Immunodeficiency Virus (HIV) Ribonucleic Acid in Cerebrospinal Fluid and Blood Is Linked to CD4/CD8 Ratio During Acute HIV. J Infect Dis. 2018 Aug 14;218(6):937-945. doi: 10.1093/infdis/jiy260. 

Samboju V, Philippi CL, Chan P, et al. Structural and functional brain imaging in acute HIV. Neuroimage Clin. 2018 Jul 27;20:327-335. doi: 10.1016/j.nicl.2018.07.024. eCollection 2018.

Colby DJ, Trautmann L, Pinyakorn S, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11.

Teigler JE, Leyre L, Chomont N, et al. Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. JCI Insight. 2018 May 17;3(10). pii: 98420. doi: 10.1172/jci.insight.98420. [Epub ahead of print]

Crowell TA, Colby DJ, Pinyakorn S, et al. Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. Clin Infect Dis. 2018 May 2;66(10):1540-1549. doi: 10.1093/cid/cix1063. 

Chan P, Hellmuth J, Colby D, et al. Safety of lumbar puncture procedure in an international research setting during acute HIV infection. J Virus Erad. 2018 Jan 1;4(1):16-20. 

Henderson GE, Peay HL, Kroon E, et al. Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. J Med Ethics. 2018 Apr;44(4):270-276. doi: 10.1136/medethics-2017-104433. Epub 2017 Nov 10. 

Hellmuth J, Colby D, Valcour V, et al. Depression and Anxiety are Common in Acute HIV Infection and Associate with Plasma Immune Activation. AIDS Behav. 2017 Nov;21(11):3238-3246. doi: 10.1007/s10461-017-1788-4. 

Sacdalan C, Crowell T, Colby D, et al. Brief Report: Safety of Frequent Blood Sampling in Research Participants in an Acute HIV Infection Cohort in Thailand. J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):98-101. doi: 10.1097/QAI.0000000000001436. 

Kroon EDMB, Phanuphak N, Shattock AJ, et al. Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in Bangkok. J Int AIDS Soc. 2017 Jun 28;20(1):21708. doi: 10.7448/IAS.20.1.21708. 

Ananworanich J, Eller LA, Pinyakorn S, et al. Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand. J Int AIDS Soc. 2017 Jun 26;20(1):21652. doi: 10.7448/IAS.20.1.21652. 

Kessing CF, Spudich S, Valcour V,  et al. High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. J Acquir Immune Defic Syndr. 2017 May 1;75(1):108-117. doi: 10.1097/QAI.0000000000001301. 

Takata H, Buranapraditkun S, Kessing C, et al. Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection. Sci Transl Med. 2017 Feb 15;9(377). pii: eaag1809. doi: 10.1126/scitranslmed.aag1809. 

Peluso MJ, Valcour V, Phanuphak N, et al. Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. AIDS. 2017 Jan 14;31(2):247-252. doi: 10.1097/QAD.0000000000001314. 

Colby DJ, Crowell TA, Sirivichayakul S, et al. Declining trend in transmitted drug resistance detected in a prospective cohort study of acute HIV infection in Bangkok, Thailand. J Int AIDS Soc. 2016 Oct 31;19(1):20966. doi: 10.7448/IAS.19.1.20966. 

Sereti I, Krebs SJ, Phanuphak N, et al. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. Clin Infect Dis. 2017 Jan 15;64(2):124-131. doi: 10.1093/cid/ciw683. Epub 2016 Oct 12. 

Crowell TA, Fletcher JL, Sereti I, et al. Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. J Int AIDS Soc. 2016 Sep 15;19(1):21163. doi: 10.7448/IAS.19.1.21163. 

Crowell TA, Phanuphak N, Pinyakorn S, et al. Virologic failure is uncommon after treatment initiation during acute HIV infection. AIDS. 2016 Jul 31;30(12):1943-50. doi: 10.1097/QAD.0000000000001148. 

Muir R, Metcalf T, Tardif V, et al. Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection. PLoS Pathog. 2016 Jul 27;12(7):e1005777. doi: 10.1371/journal.ppat.1005777. 

Ananworanich J, Chomont N, Eller LA, et al. HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine. 2016 Sep;11:68-72. doi: 10.1016/j.ebiom.2016.07.024. Epub 2016 Jul 20. 

Deleage C, Schuetz A, Alvord WG, et al. Impact of early cART in the gut during acute HIV infection. JCI Insight. 2016 Jul 7;1(10). pii: e87065. 

de Souza MS, Pinyakorn S, Akapirat S, et al. Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology. Clin Infect Dis. 2016 Aug 15;63(4):555-61. doi: 10.1093/cid/ciw365. Epub 2016 Jun 17. 

Hellmuth J, Fletcher JL, Valcour V, et al. Neurologic signs and symptoms frequently manifest in acute HIV infection. Neurology. 2016 Jul 12;87(2):148-54. doi: 10.1212/WNL.0000000000002837. Epub 2016 Jun 10. 

Ananworanich J, Sacdalan CP, Pinyakorn S, et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad. 2016;2:43-48. 

Kore I, Ananworanich J, Valcour V, et al. Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):393-9. doi: 10.1097/QAI.0000000000000746. 

Valcour VG, Spudich SS, Sailasuta N, et al. Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV. PLoS One. 2015 Nov 10;10(11):e0142600. doi: 10.1371/journal.pone.0142600. 

Peluso MJ, Valcour V, Ananworanich J, et al. Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. J Infect Dis. 2015 Dec 1;212(11):1759-67. doi: 10.1093/infdis/jiv296. Epub 2015 May 20. 

Phanuphak N, Teeratakulpisarn N, van Griensven F, et al. Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens. J Int AIDS Soc. 2015 May 7;18:19470. doi: 10.7448/IAS.18.1.19470. 

De Souza MS, Phanuphak N, Pinyakorn S, et al. Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection. AIDS. 2015 Apr 24;29(7):793-800. doi: 10.1097/QAD.0000000000000616. 

Ananworanich J, Chomont N, Fletcher JL, et al. Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. J Virus Erad. 2015;1(2):116-122. Epub 2015 Apr 1. 

Ananworanich J, Sirivichayakul S, Pinyakorn S, et al. High prevalence of transmitted drug resistance in acute HIV-infected Thai men who have sex with men. J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):481-5. doi: 10.1097/QAI.0000000000000502. 

Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014 Dec 11;10(12):e1004543. doi: 10.1371/journal.ppat.1004543. 

Ananworanich J, Fletcher JL, Pinyakorn S, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology. 2013 May 29;10:56. doi: 10.1186/1742-4690-10-56. 

Sailasuta N, Ross W, Ananworanich J, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One. 2012;7(11):e49272. doi: 10.1371/journal.pone.0049272. Epub 2012 Nov 16. 

Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012 Jul 15;206(2):275-82. doi: 10.1093/infdis/jis326. Epub 2012 May 2. 

Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. 2012;7(3):e33948. doi: 10.1371/journal.pone.0033948. Epub 2012 Mar 30. 

Observational Studies

CODEX cohort (ANRS CO21)

References

Hage-Sleiman M, Tremeaux P, Fillion M, et al. False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers. Clin Infect Dis. 2019 Sep 21. pii: ciz734. doi: 10.1093/cid/ciz734. [Epub ahead of print]

Avettand-Fenoel V, Bayan T, Gardiennet E, et al. Dynamics in HIV-DNA levels over time in HIV controllers. J Int AIDS Soc. 2019 Jan;22(1):e25221. doi: 10.1002/jia2.25221.

Ploquin MJ, Casrouge A, Madec Y, et al. Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage. J Int AIDS Soc. 2018 Jul;21(7):e25144. doi: 10.1002/jia2.25144.

Claireaux M, Galperin M, Benati D, et al. A High Frequency of HIV-Specific Circulating Follicular Helper T Cells Is Associated with Preserved Memory B Cell Responses in HIV Controllers. MBio. 2018 May 8;9(3). pii: e00317-18. doi: 10.1128/mBio.00317-18.

Chaix ML, Boufassa F, Meyzer C, et al. Detectable HIV-RNA in semen of HIV controllers. PLoS One. 2017 Aug 16;12(8):e0183376. doi: 10.1371/journal.pone.0183376. eCollection 2017.

Canouï E, Lécuroux C, Avettand-Fenoël V, et al. A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infect Dis. 2017 Apr 3;4(2):ofx064. doi: 10.1093/ofid/ofx064. 

Canoui E, Noël N, Lécuroux C, et al. Strong ifitm1 Expression in CD4 T Cells in HIV Controllers Is Correlated With Immune Activation. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):e56-e59. doi: 10.1097/QAI.0000000000001166. 

Hamimi C, David A, Versmisse P, et al. Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles. PLoS One. 2016 Aug 9;11(8):e0160251. doi: 10.1371/journal.pone.0160251.

Benati D, Galperin M, Lambotte O, et al. Public T cell receptors confer high-avidity CD4 responses to HIV controllers. J Clin Invest. 2016 Jun 1;126(6):2093-108. doi: 10.1172/JCI83792. Epub 2016 Apr 25.

Noel N, Lerolle N, Lécuroux C, et al. Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study. PLoS One. 2015 Jul 6;10(7):e0131922. doi: 10.1371/journal.pone.0131922.

Noel N, Boufassa F, Lécuroux C, et al. Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients. AIDS. 2014 Feb 20;28(4):467-76. doi: 10.1097/QAD.0000000000000174.

FRESH (Females rising through education, support, and health)
Ragon Institute webpage (no clinicaltrials.gov entry)

References

Ndhlovu ZM, Kazer SW, Nkosi T, et al. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. Sci Transl Med. 2019 May 22;11(493). pii: eaau0528. doi: 10.1126/scitranslmed.aau0528.

Piantadosi A, Freije CA, Gosmann C et al. Metagenomic sequencing of HIV-1 in the blood and female genital tract reveals little quasispecies diversity during acute infection. J Virol. 2018 Oct 31. pii: JVI.00804-18. doi: 10.1128/JVI.00804-18. [Epub ahead of print]

Ndung'u T, Dong KL, Kwon DS, Walker BD. A FRESH approach: Combining basic science and social good. Sci Immunol. 2018 Sep 14;3(27). pii: eaau2798. doi: 10.1126/sciimmunol.aau2798. 

Dong KL, Moodley A, Kwon DS, et al. Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study. Lancet HIV. 2018 Jan;5(1):e35-e44. doi: 10.1016/S2352-3018(17)30146-7. Epub 2017 Oct 1. 

Mabuka JM, Dugast AS, Muema DM, et al. Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. Front Immunol. 2017 Sep 8;8:1104. doi: 10.3389/fimmu.2017.01104.

Lee GQ, Orlova-Fink N, Einkauf K, et al. Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J Clin Invest. 2017 Jun 30;127(7):2689-2696. doi: 10.1172/JCI93289. Epub 2017 Jun 19. 

Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. Immunity. 2017 Jan 17;46(1):29-37. doi: 10.1016/j.immuni.2016.12.013. Epub 2017 Jan 10. 

Kløverpris HN, Kazer SW, Mjösberg J, et al. Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. Immunity. 2016 Feb 16;44(2):391-405. doi: 10.1016/j.immuni.2016.01.006. Epub 2016 Feb 2. 

Byrne EH, Anahtar MN, Cohen KE, et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet Infect Dis. 2016 Apr;16(4):441-8. doi: 10.1016/S1473-3099(15)00429-6. Epub 2015 Dec 24. 

Ndhlovu ZM, Kamya P, Mewalal N, et al. Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity. 2015 Sep 15;43(3):591-604. doi: 10.1016/j.immuni.2015.08.012. Epub 2015 Sep 8. 

Anahtar MN, Byrne EH, Doherty KE, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 2015 May 19;42(5):965-76. doi: 10.1016/j.immuni.2015.04.019. 

PRIMO Cohort (ANRS CO6)

References

Trémeaux P, Lenfant T, Boufassa F, et al. Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection. EBioMedicine. 2019 Mar;41:455-464. doi: 10.1016/j.ebiom.2019.02.016. Epub 2019 Feb 23.

Avettand-Fénoël V, Mélard A, Gueudin M, et al. Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: Underestimation of some CRF02 strains. J Clin Virol. 2019 Jan;110:36-41. doi: 10.1016/j.jcv.2018.12.002. Epub 2018 Dec 3.

Beretta M, Moreau A, Bouvin-Pley M, et al. Phenotypic properties of envelope glycoproteins of transmitted HIV-1 variants from patients belonging to transmission chains. AIDS. 2018 Sep 10;32(14):1917-1926. doi: 10.1097/QAD.0000000000001906.

Ploquin MJ, Casrouge A, Madec Y, et al. Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage. J Int AIDS Soc. 2018 Jul;21(7):e25144. doi: 10.1002/jia2.25144.

Coindre S, Tchitchek N, Alaoui L, et al. Mass Cytometry Analysis Reveals the Landscape and Dynamics of CD32a+ CD4+ T Cells From Early HIV Infection to Effective cART. Front Immunol. 2018 Jun 4;9:1217. doi: 10.3389/fimmu.2018.01217. eCollection 2018.

Stefic K, Novelli S, Mahjoub N, et al. Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection. J Infect Dis. 2018 May 5;217(11):1793-1797. doi: 10.1093/infdis/jiy120.

Novelli S, Lécuroux C, Avettand-Fenoel V, et al. Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection. Clin Infect Dis. 2018 May 2;66(10):1519-1527. doi: 10.1093/cid/cix1068.

Krastinova E, Seng R, Lechenadec J, et al. Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption? BMC Infect Dis. 2015 Apr 10;15:178. doi: 10.1186/s12879-015-0892-1.

Krastinova E, Lecuroux C, Leroy C, et al. High Soluble CD14 Levels at Primary HIV-1 Infection Predict More Rapid Disease Progression. J Infect Dis. 2015 Sep 15;212(6):909-13. doi: 10.1093/infdis/jiv145. Epub 2015 Mar 6.

Laanani M, Ghosn J, Essat A, et al. Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA. Clin Infect Dis. 2015 Jun 1;60(11):1715-21. doi: 10.1093/cid/civ171. Epub 2015 Mar 3.

Seng R, Goujard C, Krastinova E, et al. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy. AIDS. 2015 Mar 13;29(5):595-607. doi: 10.1097/QAD.0000000000000571.

Calin R, Fourati S, Schneider L, et al. Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure. J Antimicrob Chemother. 2015 Jan;70(1):317-9. doi: 10.1093/jac/dku370. Epub 2014 Sep 19. 

Krastinova E, Seng R, Yeni P, et al. Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts. PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. 

Frange P, Meyer L, Ghosn J, et al. Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection. Clin Microbiol Infect. 2013 May;19(5):E252-5. doi: 10.1111/1469-0691.12127. Epub 2013 Jan 17.

Huang X, Lodi S, Fox Z, et al. Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a.

Chaix ML, Seng R, Frange P, et al. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis. 2013 Mar;56(6):880-7. doi: 10.1093/cid/cis999. Epub 2012 Dec 7.

Rachas A, Warszawski J, Le Chenadec J, et al. Does pregnancy affect the early response to cART? AIDS. 2013 Jan 28;27(3):357-67. doi: 10.1097/QAD.0b013e32835ac8bc.

Leruez-Ville M, Seng R, Morand P, et al. Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma. HIV Med. 2012 Sep;13(8):479-87. doi: 10.1111/j.1468-1293.2012.00998.x. Epub 2012 Mar 14.

Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

Ghosn J, Persoz A, Zitoun Y, et al. Thrombocytopenia during primary HIV-1 infection predicts the risk of recurrence during chronic infection. J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):e112-4. doi: 10.1097/QAI.0b013e31825b6fde. 

Pantazis N, Morrison C, Amornkul PN, et al. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One. 2012;7(3):e32369. doi: 10.1371/journal.pone.0032369. Epub 2012 Mar 6.

Ghosn J, Galimand J, Raymond S, et al. X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI. PLoS One. 2011;6(8):e23301. doi: 10.1371/journal.pone.0023301. Epub 2011 Aug 24.

Ghosn J, Galimand J, Meyer L, et al. Undetectable HIV-1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV-1 infection. J Med Virol. 2010 Nov;82(11):1816-8. doi: 10.1002/jmv.21827.

Frange P, Chaix ML, Raymond S, et al. Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol. 2010 Oct;48(10):3487-91. doi: 10.1128/JCM.00704-10. Epub 2010 Aug 4. 

Galimand J, Frange P, Rouzioux C, et al. Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997-2007 in France: ANRS CO06 PRIMO Cohort. AIDS Res Hum Retroviruses. 2010 Jun;26(6):645-51. doi: 10.1089/aid.2009.0201.

Ghosn J, Deveau C, Chaix ML, et al. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother. 2010 Apr;65(4):741-8. doi: 10.1093/jac/dkq035. Epub 2010 Feb 18.

Louis S, Dutertre CA, Vimeux L, et al. IL-23 and IL-12p70 production by monocytes and dendritic cells in primary HIV-1 infection. J Leukoc Biol. 2010 Apr;87(4):645-53. doi: 10.1189/jlb.1009684. Epub 2010 Jan 22.

Lewden C, Thiébaut R, Boufassa F, et al. Comparison of early CD4 T-cell count in HIV-1 seroconverters in Côte d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts. J Acquir Immune Defic Syndr. 2010 Feb;53(2):260-5. doi: 10.1097/QAI.0b013e3181b84260.

Goujard C, Chaix ML, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis. 2009 Sep 15;49(6):982-6. doi: 10.1086/605504.

Lécuroux C, Girault I, Boutboul F, et al. Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells. AIDS. 2009 Aug 24;23(13):1649-58. doi: 10.1097/QAD.0b013e32832e6634.

Troude P, Chaix ML, Tran L, et al. No evidence of a change in HIV-1 virulence since 1996 in France. AIDS. 2009 Jun 19;23(10):1261-7. doi: 10.1097/QAD.0b013e32832b51ef.

Frange P, Galimand J, Goujard C, et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother. 2009 Jul;64(1):135-41. doi: 10.1093/jac/dkp151. Epub 2009 May 2.

Chaix ML, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS. 2009 Mar 27;23(6):717-24. doi: 10.1097/QAD.0b013e328326ca77.

Seng R, Goujard C, Desquilbet L, et al. Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):251-8. doi: 10.1097/QAI.0b013e318189a739.

Frange P, Galimand J, Vidal N, et al. New and old complex recombinant HIV-1 strains among patients with primary infection in 1996-2006 in France: the French ANRS CO06 primo cohort study. Retrovirology. 2008 Aug 1;5:69. doi: 10.1186/1742-4690-5-69.

Chaix ML, Desquilbet L, Descamps D, et al. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther. 2007;12(8):1305-10.

Courgnaud V, Seng R, Becquart P, et al. HIV-1 co-infection prevalence in two cohorts of early HIV-1 seroconverters in France. AIDS. 2007 May 11;21(8):1055-6. 

Adalid-Peralta L, Grangeot-Keros L, Rudent A, et al. Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med. 2006 Nov;7(8):514-9. 

Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS. 2006 Jan 9;20(2):159-70.

Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis. 2006 Mar 1;42(5):709-15. Epub 2006 Jan 24.

Dray-Spira R, Gueguen A, Persoz A, et al. Temporary employment, absence of stable partnership, and risk of hospitalization or death during the course of HIV infection. J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):190-7.

Desquilbet L, Goujard C, Rouzioux C, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS. 2004 Dec 3;18(18):2361-9.

Schiffer V, Deveau C, Meyer L, et al. Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort. HIV Med. 2004 Sep;5(5):326-33.

Ngo-Giang-Huong N, Deveau C, Da Silva I, et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS. 2001 Apr 13;15(6):665-73.